|
⚲
|
| Keyboard |
| Avidity Partners Management LP
✚
|
|
|---|---|
| CRD # | 304628 |
| SEC # | 801-118809 |
| CIK # | 0001791827 |
| AUM | 1,059.2 M (2026-03-31) |
| Employees | 9 (78% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 214-550-1696 |
| Address | 2828 N Harwood St, Suite 1220 Dallas, TX 75201 |
| Source | [IAPD] [EDGAR] [LinkedIn] |
| Total AUM ($B) |
|---|
| In the News | |
|---|---|
| Sat, 01 Aug 2026 | 950,000 Shares in Vir Biotechnology, Inc. $VIR Bought by Avidity Partners Management LP — MarketBeat |
| Sat, 01 Aug 2026 | Avidity Partners Management LP Takes $1.11 Million Position in Abivax SA Sponsored ADR $ABVX — MarketBeat |
| Sat, 01 Aug 2026 | Avidity Partners Management LP Sells 132,800 Shares of Kenvue Inc. $KVUE — MarketBeat |
| Sat, 01 Aug 2026 | Avidity Partners Management LP Buys Shares of 25,000 Humana Inc. $HUM — MarketBeat |
| Sat, 01 Aug 2026 | Avidity Partners Management LP Acquires New Position in Peloton Interactive, Inc. $PTON — MarketBeat |
| Fees and Compensation — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
Item 5: Fees and Compensation DESCRIPTION OF COMPENSATION AND BASIC FEE SCHEDULE In consideration of our advisory services, We generally receive management fees and performance-based compensation allocations with respect to the Funds, which are deducted by instructing such fund’s administrator and/or custodian. While our fees are described in detail in the Funds’ offering and governing documents, a brief summary of our advisory fees is set forth below. The Master Fund pays to the Adviser a management fee, calculated at an annual rate of (i) 1.75% of each limited partner’s capital account attributable to Founders’ Interests and (ii) 2.0% of each limited partner’s capital account attributable to Series A Interests. Fund II pays the Adviser a management fee calculated at an annual rate of 1.0% of each limited partner’s capital account. The management fee is paid quarterly in advance based on the value of each limited partner’s capital account, including Special Investments (described below) valued at fair value as determined by the Adviser, as of the first day of each calendar quarter or on the date of a contribution that is made other than at the beginning of a quarter. In general, the portion of the management fee attributable to a particular Special Investment will be charged to the special capital accounts of only those limited partners participating in the Special Investment. The management fee will be deducted in calculating net profit or net loss of the Funds for purposes of computing the Incentive Allocation described below. To the extent the management fee is paid by the Master Fund, no management fee will be paid by the Onshore Fund and Offshore Fund. The management fee is adjusted for contributions and withdrawals made during the quarter. The Adviser, in its sole discretion, may and has waived or modified the management fee for limited partners that are members, principals, employees or affiliates of the Adviser or the General Partner, relatives of such persons, and for certain large or strategic investors. For the Avidity Master Fund and Fund II, at the end of each fiscal year, Avidity will reallocate from the capital account of each limited partner to the General Partner an amount equal to 20% of each limited partner’s share of net profits (including net unrealized gains on investments) as of that fiscal year (the “Incentive Allocation”). The Incentive Allocation is subject to a loss carryforward provision and is calculated separately with respect to each capital contribution. Generally, the General Partner will not charge an Incentive Allocation on Special Investments until the end of the year that the relevant Special Investment is sold (or deemed sold). At the time a Special Investment is sold (or deemed sold), each relevant special capital account will be liquidated and the balance in it credited to the participating limited partners’ basic capital accounts. However, if a Special Investment is sold (or deemed sold) after a participating limited partner has fully withdrawn its basic capital account, the Incentive Allocation will be charged at the time the relevant Special Investment is sold (or deemed sold). The management fee and Incentive Allocation for Fund II has been separately negotiated. The General Partner, in its sole discretion, may and has waived or modified the Incentive Allocation for limited partners that are members, principals, employees or affiliates of the General Partner or the Adviser, relatives of such persons, and for certain large or strategic investors. For the Private Fund I, the management fee for each calendar quarter that begins during the fund’s investment periods will be equal to: (i) 1.50% per annum of the fund’s aggregate capital commitments for Founders’ Interests, (ii) 1.75% per annum of the fund’s aggregate capital commitments for Series A Interests and (iii) 2.0% per annum of the fund’s aggregate capital commitments for Series B Interests. The management fee for each calendar quarter that begins after the investment period ends will be equal to: (i) 1.25% per annum of the fund’s invested capital attributable to Founders’ Interests, (ii) 1.25% per annum of the fund’s invested capital attributable to Series A Interests and (iii) 1.50% per annum of the fund’s invested capital attributable to Series B Interests. In the event that the General Partner or its affiliates receive any directors’ fees from portfolio companies, transactions fees, closing fees, monitoring fees, amendment fees, break-up fees or any other similar advisory fees in connection with any services provided by the General Partner or its affiliates to a portfolio company, net of any related expenses and taxes incurred (collectively, “Transaction Fees”), then an amount equal to 100% of all Transaction Fees will offset and reduce the amount of the management fees otherwise payable to the Adviser with respect to the quarterly period immediately following the receipt of such fees. If the offset portion of the Transaction Fees received by the General Partner or affiliates during any relevant quarterly period exceeds the management fee otherwise payable with respect to that quarterly period, then the excess will be carried forward to offset and reduce the management fees otherwise payable in succeeding quarterly periods. For the avoidance of doubt, if the Private Master Fund and one or more other clients of the General Partner or Adviser have made an investment in a transaction producing Transaction Fees (or were pursuing the investment in the case of unconsummated transactions), then only the portion of the fee that is allocable to the fund determined on a pro rata basis based on relative investment in the portfolio company paying the relevant Transaction Fee will be included in the management fee offset described above. In addition, to the extent that any Transaction Fees ... |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
Item 7: Types of Clients DESCRIPTION We currently provide investment advisory, management and other services to our affiliated Funds. The Funds have various types of investors, including, but not limited to, trusts, family offices, natural persons, funds of funds, individual retirement accounts and other entities. We may from time to time provide investment advisory and other services to other clients in the future, including separately managed accounts and/or one or more other pooled investment vehicles. ACCOUNT REQUIREMENTS The minimum initial capital contribution generally required from an investor in the Onshore Fund and Offshore Fund is $5 million, although capital contributions of lesser amounts may and are accepted at the Adviser’s sole discretion. Private Fund I is closed to new investors. Each investor in the Funds generally must be, among other things, an (i) “accredited investor,” as such term is defined in Rule 501(a) under the Securities Act, and (ii) a “qualified purchaser,” as such term is defined in Section 2(a)(51)(A) of the Company Act. In addition, each prospective investor generally is required to complete and return various subscription documents to the applicable fund, which are designed to provide the applicable fund, us and our affiliates and agents with important information about the prospective investor. Subscriptions may be accepted or rejected, in whole or in part, at the sole discretion of the General Partner. |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Magenta Therapeutics Inc | 0.4 | ||
| ARCA Biopharma Inc | 0.1 | ||
| CG Oncology Inc | 0.1 | ||
| Aerovate Therapeutics Inc | 0.1 | ||
| Isoray Inc | 0.0 | ||
| Imara Inc | 0.0 | ||
| Context Therapeutics Inc | 0.0 | ||
| Teva Pharmaceutical Industries Ltd | 0.0 | ||
| Repligen Corp | 0.0 | ||
| Marika Inc | 0.0 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | Avidity Private Master Fund I LP | [2022-03-14] | 169.2 M | 480.3 M |
| Filed 2022-11-23 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| HF | Avidity Master Fund III LP | [2021-03-31] | 30.0 M | |
| Filed 2023-02-22 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Avidity Capital Fund II LP | [2020-04-27] | 197.9 M | 24.6 M |
| Filed 2024-02-22 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Avidity Master Fund LP | [2019-10-07] | 1,067.3 M | 554.3 M |
| Filed 2025-09-26 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 7 | 1.1 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 7 | 1.1 |
| By Discretionary | ||
| Discretionary | 7 | 1.1 |
| Non-Discretionary | 0 | 0.0 |
| Total | 7 | 1.1 |
| By Non-United States Persons | ||
| Non-United States Persons | 1.0 | |
| United States Persons | 0.0 | |
| Total | 7 | 1.1 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Georgia Prinsloo | Director | 156 | 37 | |
| Russell Burt | Director | 113 | 29 | |
| Avidity Partners Management LP | Executive Officer | 7 | 2 | |
| Avidity Capital Partners Fund GP LP | Executive Officer | 6 | 2 | |
| Michael Gregory | Director | 6 | 2 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001791827] | |
| 3 | [0001791827] | |
| 4 | [0001791827] | |
| SC 13D | [0001791827] | |
| SC 13G | [0001791827] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| LEI | 5493008LOMI55YUT1518 |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Dianthus Therapeutics Inc /DE/ | |
| Avidity Partners Management LP | |
| Gregory Michael David | |
| Meng Lei | |
| Witzke David Roy | |
| Avidity Partners Management GP LLC |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Dianthus Therapeutics Inc /DE/ DNTH
Common Stock
|
2024-01-22 | Grant | 1,500,000 | $12.00 | 18,000,000 |
|
Dianthus Therapeutics Inc /DE/ DNTH
Pre-Funded Warrants (Right to Buy) · derivative
|
2024-01-22 | Grant | 1,833,333 | $12.00 | 21,999,996 |
|
Dianthus Therapeutics Inc /DE/ DNTH
Stock Option (Right to Buy) · derivative
|
2023-09-11 | Grant | 6,500 | $0.00 |
| Comparable Firms | State | AUM |
|---|---|---|
|
Upper90 Capital Management LP
✚
|
RI | 1,105.3 M |
|
5AM Venture Management LLC
✚
|
CA | 1,084.3 M |
|
FJ Capital Management LLC
✚
|
VA | 1,079.8 M |
|
Forester Capital LLC
✚
|
CT | 1,070.8 M |
|
Caltius Capital Management LP
✚
|
CA | 1,064.9 M |
|
Preston Capital LLC
✚
|
CA | 1,054.6 M |
|
Whitefort Capital Management LP
✚
|
NY | 1,051.1 M |
|
1543 Capital LP
✚
|
CT | 1,038.0 M |
|
Bay Point Advisors LLC
✚
|
GA | 1,034.0 M |
|
Theorem Partners LLC
✚
|
NY | 1,032.4 M |